human and mouse P-gp efflux capacity for imatinib, it is clear that imatinib is an in vivo substrate for mouse P-gp. 7,8 We believe the differences in imatinib resistance seen when comparing the K562 data by Rumpold et al. with our data in P-gp null mice is best explained by the possibility that CML stem cells express other ABC transporters that may provide a redundant efflux mechanism for imatinib. The lack of expression of these compensatory transporters in K562 cells could therefore explain the sensitizing effect of decreased expression of P-gp in K562 cells. For instance, we have shown that K562 cells do not express ABCG2 (unpublished data) while primary hematopoietic stem cells express significant levels.
hRap1B-retro: a novel human processed Rap1B gene blurs the picture? In the September issue of Leukemia, Gyan et al. 1 report on the expression of a mutant Rap1B cDNA in myelodysplastic syndromes (MDS). Specifically, they detect a cDNA with point mutations, as compared to the wild-type Rap1B gene, that cause two amino-acid substitutions (G12R and K42E). Unfortunately, the authors could not perform an analysis of genomic DNA, which would directly reveal the relation between the Rap1B gene and the mutant cDNA. Although they point out correctly that the encoded protein most likely constitutes an activated form of Rap1B protein, we hereby present strong evidence that the detected cDNA does not originate from mutation of the Rap1B gene on chromosome 12.
An alternative explanation can be offered invoking the existence of an expressed processed gene, which we have named hRap1B-retro, located on chromosome 5 q13.3 (GI: 51465008). As it is the case for all processed genes, 2 this retrogene was generated by a LINE-1 retrotransposon 3 from the mRNA of Rap1B gene. The nucleotide sequence of the fulllength coding region of hRap1B-retro differs only at three positions from that of the mother Rap1B gene (Figure 1) . Two of these changes are identical to the reported mutations (G12R and K42E; GGA-CGA and AAG-GAG, respectively), with the third mutation being a silent one (G77G; GGA-GGG). The latter corresponds to a region in the cDNA that was not analysed by the authors.
Direct evidence for expression of hRap1B-retro comes from analysis of full-length expressed cDNAs deposited in the NCBI database. Interestingly, three of the cDNAs were cloned from a Ramos Burkitt's lymphoma cell line (GIs: 50475494, 50474682, 50470789), one was isolated from a neuroblastoma cell line (GI: 50498405), and one from a placental library (GI: 50492447). These sequences map exactly onto the genomic DNA sequence on chromosome 5 (Figure 1, Supplementary Figure 1) , revealing a structure of the hRap1B-retro gene with two exons (Figure 1,  Supplementary Figure 2) . As genomic sequences of processed genes are expected to lack intronic sequences, we set out to analyse this observed peculiarity closely. We found that the intron was created via LINE-1-mediated insertion of the SVA element into a preferred target site sequence (TTTT/AA) 4 present in hRap1B mRNA at 1304 (GI: 58219793). Since this intronic region is missing from the sequences of the five deposited in database cDNAs, it is evident that they represent transcribed and spliced sequences rather than contaminating genomic DNA.
In conclusion, we think that it is highly likely that the mutant Rap1B cDNA reported by the authors is actually derived from expression of the hRap1B-retro gene in the MDS cells. Whether this may have contributed to the development of MDS, and possibly other malignancies (i.e. Burkitt's lymphoma), will require a more extensive analysis of the encoded gene product. For example, it should be determined whether the protein is indeed more GTP-bound. We would like to remark that we also found processed Rap1 genes in the mouse genome (manuscript in preparation; Marlena Duchniewicz, Taisa Paluch, Fried Zwartkruis and Tomasz Zemojtel). It should be noted that the existence of a functional processed gene belonging to Ras family has been reported previously. Intriguingly, the human ERas encodes an activated (i.e. GTP-bound) version of Ras and was shown to transform NIH 3T3 cells oncogenically. 2 In this light, a better expression profiling of the hRap1B-retro gene identified by us will help to validate whether it defines a novel drug target.
Reply to 'hRap1B-retro: a novel human processed Rap1B gene blurs the picture?' by Zemojtel et al We agree with the comments made by Zemojtel et al. 1 and we thank them very much for the proposed hypothesis. In our work published in the September issue of Leukemia, 2 we initially used previously published oligonucleotides 3 to analyze rap1b transcript in bone marrow samples from 27 patients with myelodysplastic syndromes (MDS) and two secondary acute myeloid leukemias (sAML). In one patient with RARS and abnormal The hRap1B-retro gene is localized on chromosome 5 q13.3. Upper part: summary of differences in the sequence alignment between hRap1B-retro and hRap1B cDNAs and the corresponding genomic regions on the 5th and 12th chromosomes. In addition to the three nucleotide substitutions in the open reading frame (ORF), seven more differences between both genes are present in the untranslated regions (UTRs). The coordinates above the sequences are relative to the start codon ATG in hRap1B cDNA (GI: 58219793). hRap1B-r_Ram1-3: full-length cDNAs of hRap1B-retro from Ramos cell line (GIs: 50475494, 50474682, 50470789); hRap1B-r_Neur: full-length cDNA of hRap1B-retro from neuroblastoma (GI: 50498405); hRap1B-r_Plac: full-length cDNA of hRap1B-retro from placenta (GI: 50492447). 5chr: genomic DNA sequence from chromosome 5 (GI: 51465008: 26064529-26060269), 12chr: genomic DNA sequence from chromosome 12 (GI: 29803948: 31147958-31197631). Lower part: exonic structure of the hRap1B-retro and hRap1B mother genes mapped onto their cDNAs. Numbering stands for exon numbers.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
